Skip Navigation

Publication Detail

Title: Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer.

Authors: Neugut, Alfred I; Hillyer, Grace Clarke; Kushi, Lawrence H; Lamerato, Lois; Leoce, Nicole; Ambrosone, Christine B; Bovbjerg, Dana H; Mandelblatt, Jeanne S; Hershman, Dawn L

Published In Breast Cancer, (2014 Nov)

Abstract: One year of trastuzumab therapy is recommended for women with HER2-positive breast cancer ≥ 1.0 cm in size to increase survival and is considered for women with tumors 0.5-0.9 cm in size. We analyzed compliance with trastuzumab among women with HER2-positive breast cancer in a prospective cohort study. Of 1145 recruited patients with breast cancer, 152 were HER2-positive (13.2 %), of whom 126 had tumors ≥ 1.0 cm; 110/126 (87.3 %) of these initiated trastuzumab. Non-receipt was associated with older age, better prognosis tumors, and with non-receipt of adjuvant chemotherapy. Of the 110 who initiated treatment, 18 (15 %) did not complete treatment, 15 (83 %) of them because of cardiotoxicity. Of 20 women with tumors 0.5-0.9 cm, 5 (25 %) initiated trastuzumab. Compliance with trastuzumab was very high among those with HER2-positive breast cancer, as was the completion of the recommended therapy.

PubMed ID: 24902664 Exiting the NIEHS site

MeSH Terms: Adult; Aged; Antibodies, Monoclonal, Humanized/adverse effects; Antibodies, Monoclonal, Humanized/therapeutic use*; Antineoplastic Agents/adverse effects; Antineoplastic Agents/therapeutic use; Breast Neoplasms/drug therapy*; Breast Neoplasms/metabolism; Breast Neoplasms/pathology; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Medication Adherence*; Middle Aged; Prognosis; Prospective Studies; Receptor, ErbB-2/metabolism; Trastuzumab; Treatment Outcome

Back
to Top